Looking at the extracerebral objective response rate, this study shows that trastuzumab and paclitaxel combination therapy is active in controlling HER2 expression and EGFR mutation positive NSCLC outside the CNS with an extracerebral response rate of 58%. Here, ERBB2 is linked to non-small cell lung carcinoma.